Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SALUTENSIN-DEMI vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydroflumethiazide is minimally metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Hydrochlorothiazide: 40-68% (primarily to albumin); Reserpine: approximately 40% (to albumin and α1-acid glycoprotein)
~90%, primarily to albumin
Hydrochlorothiazide: 0.2-0.4 L/kg (distributes in extracellular fluid); Reserpine: 5-10 L/kg (extensive tissue distribution, high affinity for adrenergic neurons)
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: hydrochlorothiazide 65-75%; reserpine 30-50% (extensive first-pass metabolism)
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in GFR <30 m L/min. For GFR 30-50 m L/min: use maximum 1 tablet daily; monitor electrolytes and renal function.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., every other day). Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for pediatric use due to lack of safety and efficacy data; alternative agents preferred.
Not recommended for pediatric use; safety in children under 12 years not established.
Start with 0.5 tablet (7.5 mg hydrochlorothiazide + 0.0375 mg clonidine) once daily; monitor for orthostatic hypotension, electrolyte imbalance, and renal function; avoid in patients with high frailty.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None.
None
Electrolyte imbalances (hypokalemia, hyponatremia),Orthostatic hypotension,Depression (reserpine component),Potential for increased risk of non-melanoma skin cancer with thiazide diuretics,May exacerbate systemic lupus erythematosus
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Known hypersensitivity to sulfonamide-derived drugs (hydroflumethiazide),Anuria,History of mental depression (reserpine-containing products),Active peptic ulcer or ulcerative colitis,Concomitant use with MAO inhibitors
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, leafy greens) as thiazide can cause potassium loss; however, reserpine may increase potassium retention. Maintain balanced diet. Limit sodium intake to control blood pressure. Avoid grapefruit juice as it may increase reserpine absorption.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydramnios, skull ossification delay. Avoid use unless benefit outweighs risk.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted in breast milk; M/P ratio not reported. Risk of infant hypotension and renal impairment. Use caution, monitor infant blood pressure and renal function.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Dose may need reduction due to increased volume of distribution and altered drug clearance. Adjust based on clinical response and maternal blood pressure. Monitor for hypotension and electrolyte imbalance.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Salutensin-demi contains reserpine (rauwolfia alkaloid) and a thiazide diuretic. Monitor for depression, nasal stuffiness, and hypotension. Avoid concurrent MAOIs. Use with caution in patients with a history of peptic ulcer disease due to increased gastric acid secretion from reserpine.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed, usually once daily in the morning.,Avoid sudden discontinuation; taper dose to prevent rebound hypertension.,Report signs of depression, nightmares, or severe drowsiness.,May cause dizziness upon standing; rise slowly from sitting or lying.,Notify your doctor if you develop abdominal pain, black stools, or unusual bleeding.,Avoid alcohol, which can increase drowsiness and hypotension.,Take with food or milk to lessen stomach upset.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SALUTENSIN-DEMI vs ALDORIL 15, answered by our medical review team.
SALUTENSIN-DEMI is a Antihypertensive Combination that works by Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SALUTENSIN-DEMI and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SALUTENSIN-DEMI is: 1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SALUTENSIN-DEMI and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SALUTENSIN-DEMI is classified as Category C. First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydr. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.